Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Mar 28;6(5):ofz168.
doi: 10.1093/ofid/ofz168. eCollection 2019 May.

Ceftaroline-Associated Neutropenia: Case Series and Literature Review of Incidence, Risk Factors, and Outcomes

Eva L Sullivan  1 , R Brigg Turner  2 , Hollis R O'Neal Jr  3 , Nancy F Crum-Cianflone  4   5
Affiliations
Review

Ceftaroline-Associated Neutropenia: Case Series and Literature Review of Incidence, Risk Factors, and Outcomes

Eva L Sullivan et al. Open Forum Infect Dis. .

Abstract

Ceftaroline is increasingly prescribed for "off-label" indications involving longer durations and higher doses. There have been postmarketing case reports of neutropenia among patients who have received extended durations of ceftaroline, but limited published data currently exist on its incidence and risk factors. We review a total of 37 published cases of ceftaroline-associated neutropenia including cases (n = 4) identified in our health care system. The median time from ceftaroline initiation to development of neutropenia (range) was 25 (8-125) days, with a median duration of neutropenia (range) of 4 (1-16) days. Agranulocytosis (absolute neutrophil count [ANC] nadir < 100 cells/mm3) developed in 49% of cases (n = 18), and there was an ANC nadir of 0 in 27% (n = 10). The overall incidence of neutropenia among cases receiving ceftaroline for ≥7-14 days (range) was 12% (7%-18% per individual study), higher than for comparator antibiotics in the literature. Risk factors for ceftaroline-associated neutropenia varied among studies and remain poorly defined.

Keywords: ceftaroline; incidence; neutropenia; review; side effects.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Absolute neutrophil count (ANC) trajectories for current cases.
See this image and copyright information in PMC

References

    1. Naber CK. Staphylococcus aureus bacteremia: epidemiology, pathophysiology, and management strategies. Clin Infect Dis 2009; 48(Suppl 4):S231–7. - PubMed
    1. Bergin SP, Holland TL, Fowler VG Jr, Tong SYC. Bacteremia, sepsis, and infective endocarditis associated with Staphylococcus aureus. Curr Top Microbiol Immunol 2017; 409:263–96. - PubMed
    1. Britt RS, Evoy KE, Lee GC, et al. . Early use of ceftaroline fosamil in the United States Veterans Health Care System. Drugs 2017; 77:1345–51. - PMC - PubMed
    1. Meaney CJ, Hynicka LM, Tsoukleris MG. Vancomycin-associated nephrotoxicity in adult medicine patients: incidence, outcomes, and risk factors. Pharmacotherapy 2014; 34:653–61. - PubMed
    1. File TM Jr, Low DE, Eckburg PB, et al. . FOCUS 1: a randomized, double-blinded, multicentre, phase III trial of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in community-acquired pneumonia. J Antimicrob Chemother 2011; 66(Suppl 3):iii19–32. - PubMed